Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
8.02
-0.51 (-5.98%)
At close: Aug 20, 2026, 4:00 PM EDT
8.16
+0.14 (1.75%)
After-hours: Aug 20, 2026, 7:30 PM EDT
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Andrew Goldberg |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468500 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew D. Goldberg M.D. | Chief Executive Officer, President and Director |
| Erik Atkisson | Chief Legal Officer |
| Mark K. Oki CPA | Chief Financial Officer |
| Jerry Wan | Vice President of Finance and Principal Accounting Officer |
| Dr. Mark L. Rubinstein M.D. | Chief Medical Officer |
| Mark Zappia | Senior Vice President of Commercial |
| Ronald Dadino | Senior Vice President of Chemistry, Manufacturing and Controls and Supply Chain |
| Gloria Cosgrove | Senior Vice President of Quality |
| Nicole P. Jones | Vice President of Strategic Communications and Stakeholder Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2026 | 144 | Filing |
| Aug 17, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 424B5 | Filing |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 28, 2026 | SCHEDULE 13G/A | Filing |
| Jul 27, 2026 | SCHEDULE 13G | Filing |
| Jul 8, 2026 | SCHEDULE 13G | Filing |